Do You Believe in the Domestic Pharma Industry?

Add bookmark

Pharma IQ
05/25/2012

The competitive growth of domestic pharma industry manufacturers has finally become one of the top-priority objectives for the next 8 years. The long-awaited WTO accession of Russia, requirements, liabilities and consequences of this significant step, both politically and economically, will certainly have a considerable effect on both the Russian economy as a whole, and on the individual industries.

According to the forecasts of analysts, the total turnover of the Russian pharmaceutical market will amount to USD 37.15 bln in 2016, while the "Pharma-2020" strategy will raise USD 4 bln in government investments. In this context, the increase of production capacity and production process efficiency became priority areas of business activities for the key market players.

It is not surprising that all these market developments encourage the experts to come together to discuss new arising problems and find ways of solving them. In 2011-2012, the UK office of Pharma IQ organised a number of successful events with the particular focus on the Russian pharmaceutical market. The organisers believe that the success of forums and summits can be explained by the need of mutual cooperation and sharing of experience between the market players.
[inlinead]
“At present, the Government of the Russian Federation pays an especially close attention to the pharmaceutical industry”, said Alex Tyumenin, Director of the Russian division of Pharma IQ.

“Tight deadlines and tough conditions have been set to the pharma companies for the improvement of pharmaceutical production according to the international standards of GMP. Moreover, ambitious goals have been set to domestic pharmaceutical manufacturers as a whole, and the policy of rapid development of the domestic pharmaceutical production market has been adopted.

These large-scale forthcoming changes and necessity to develop a growth strategy for every individual pharmaceutical manufacturer also encouraged us to create this forum. Our main objective is to gather together leading industry experts to discuss tactics, strategy and experience in the Russian pharmaceutical market,” he said.

Inspired by the success of recent events in Russia, we are proudly presenting the first international Pharmaceutical Manufacturing Russia & CIS Forumwhich will be held in September 18-20 in Moscow.

Sanofi-Aventis Deutschland, Roche Moscow, the Society of Professional Pharmaceutical Organisations, Interfax, Sanofi-Aventis Vostok, Lilly UK, Novo Nordinsk, Pharmexpert Analitika and Consulting, Indar and many other companies have already confirmed their participation in the Forum.

The target audience of our Forum are the top managers of the pharmaceutical companies, manufacturers of pharmaceuticals and pharmaceutical equipment, contract organisations and raw material suppliers for pharmaceutical manufacturing. Managing and commercial directors, production directors as well as managers responsible for business development, sales, raw material & finished pharma product supplies are among our delegates.

Reports of our speakers will cover the most important issues the industry is facing. We are happy to be contacted by the leading experts, analysts and practitioners; we believe that this Forum will contribute to tackling the issues that the Russian pharmaceutical market is facing. And we will do our best to provide the most comfortable conditions for the Forum participants to enable efficient communication.”

If you would like to take part in our first international Pharmaceutical Manufacturing Russia & CIS Forumin Moscow, please contact us:

For speakers: Alexey Tyumenin, Director of the Forum, alex.tyumenin@iqpc.co.uk
For media partners: Julia Rotar, Marketing Manager of the Forum, julia.rotar@iqpc.co.uk
For sponsors: Gal Cohen, gal.cohen@iqpc.co.uk
For delegates: enquiry@iqpc.co.uk, +44(0) 207 368 9802.